This page tracks the validation status of molecular biomarkers for corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), two 4R-tauopathies within the atypical parkinsonism spectrum. Biomarker validation follows a phased approach from analytical validation through clinical implementation.
| Phase | Description | Key Activities |
|---|---|---|
| Phase 1: Discovery | Biomarker identification | Assay development, preliminary sensitivity testing |
| Phase 2: Analytical Validation | Assay performance | Precision, accuracy, reproducibility across labs |
| Phase 3: Clinical Validation | Diagnostic performance | Sensitivity, specificity, AUC in prospective cohorts |
| Phase 4: Clinical Utility | Real-world performance | Impact on diagnostic accuracy, treatment decisions |
| Phase 5: Implementation | Clinical adoption | Standardization, reimbursement, guideline inclusion |
Assay Platforms:
| Platform | Developer | Status | FDA Clearance |
|---|---|---|---|
| PrecivityAD2 | C2N Diagnostics | CLIA-certified | No (RUO) |
| Lumipulse | Fujirebio | CE-marked, FDA-cleared (AD) | AD only |
| ALZpath | ALZpath | Research use | No |
Key Validation Studies:
Assay Standardization:
Clinical Implementation Timeline:
Assay Platforms:
| Platform | Developer | Status | FDA Clearance |
|---|---|---|---|
| NF-light | Siemens Healthineers | CE-marked | No |
| Simoa NfL | Quanterix | CLIA-certified | No (RUO) |
| ELECSYS | Roche | CE-marked | No |
Key Validation Studies:
Assay Standardization:
Clinical Implementation Timeline:
Assay Platforms:
| Platform | Developer | Status |
|---|---|---|
| GFAP Discovery | Simoa/Quanterix | Research use |
| Lumipulse | Fujirebio | CE-marked |
| ALZpath p-tau217/GFAP combo | ALZpath | Research use |
Key Validation Studies:
Assay Standardization:
Clinical Implementation Timeline:
Assay Platforms:
| Platform | Developer | Status |
|---|---|---|
| YKL-40 ELISA | R&D Systems | Research use |
| Simoa | Quanterix | Research use |
| Olink | Olink Proteomics | Research use |
Key Validation Studies:
Assay Standardization:
Clinical Implementation Timeline:
Assay Platforms:
| Platform | Developer | Status |
|---|---|---|
| sTREM2 ELISA | R&D Systems | Research use |
| Simoa | Quanterix | Research use |
| MSD | Meso Scale Discovery | Research use |
Key Validation Studies:
Assay Standardization:
Clinical Implementation Timeline:
Assay Platforms:
| Platform | Technology | Status |
|---|---|---|
| RT-QuIC | Real-Time Quaking Induced Conversion | Research use |
| PMCA | Protein Misfolding Cyclic Amplification | Research use |
| Seed amplification | Various | Research use |
Key Validation Studies:
Assay Standardization:
Clinical Implementation Timeline:
| Biomarker | Diagnostic Utility | Progression Tracking | Treatment Response | Clinical Ready |
|---|---|---|---|---|
| p-tau217 | ★★★★☆ | ★★★☆☆ | ★★★☆☆ | 2025-2026 |
| NfL | ★★★★☆ | ★★★★★ | ★★★★☆ | Available |
| GFAP | ★★★☆☆ | ★★★☆☆ | ★★☆☆☆ | 2026-2027 |
| YKL-40 | ★★☆☆☆ | ★★☆☆☆ | ★★☆☆☆ | 2027+ |
| sTREM2 | ★★☆☆☆ | ★★★☆☆ | ★★☆☆☆ | 2027+ |
| α-syn SAA | ★★★★☆ | ★★☆☆☆ | ★☆☆☆☆ | 2026-2027 |
| Timepoint | Biomarkers | Purpose |
|---|---|---|
| Baseline | p-tau217, NfL, GFAP | Diagnostic support, prognosis |
| 6 months | NfL | Progression tracking |
| 12 months | Full panel | Reassessment, treatment decisions |
| Annual | NfL | Ongoing progression monitoring |
Blood p-tau217 accuracy for Alzheimer disease vs atypical parkinsonism (2024). 2024. ↩︎
Comparative performance of p-tau217 vs p-tau181 in atypical parkinsonism (2024). 2024. ↩︎
Quarterly validation of NfL in atypical parkinsonism (2024). 2024. ↩︎
Multi-center NfL validation in neurodegenerative diseases (2024). 2024. ↩︎
Plasma GFAP as biomarker for CBS with AD co-pathology (2024). 2024. ↩︎
YKL-40 in CBS and PSP: Neuroinflammation marker (2023). 2023. ↩︎
sTREM2 as biomarker for microglial activation in neurodegeneration (2024). 2024. ↩︎
Alpha-synuclein SAA in corticobasal syndrome (2024). 2024. ↩︎